29 pediatric Chinese patent medicines have entered the new medical insurance, nearly seven of which have become exclusive varieties

Source: menet.com March 13, 2017-03-06 medical network news related topics of the new version of the medical insurance catalog have continued from last year to now, and the popularity has never declined Earlier, it was proposed in the work plan of drug catalog that "new drugs with high clinical value should be considered when transferring in drugs, drugs with more local class B adjustments and drugs for treatment of major diseases, children's drugs, emergency rescue drugs, special drugs for occupational diseases, etc." according to the new version of medical catalog officially released at the end of February, there are 91 new children's drug varieties and drug catalog Among them, 540 drugs or dosage forms were clearly applied to children, and the guarantee of drug use for children was further strengthened According to the analysis of the internal network with a maximum of M newly added for pediatric antitussive and expectorant drugs, there are 29 newly added pediatric Chinese patent medicines, all of which are medical insurance class B, involving 161 approvals Twenty nine pediatric Chinese patent medicines involve seven categories: pediatric cough and expectoration, pediatric cold, pediatric anorexia, pediatric others, pediatric convulsion, pediatric supplementary nutrition, pediatric diarrhea Among them, the largest number of varieties is paediatric cough and expectorant drugs, there are 11 varieties, involving 105 approvals There are 6 varieties of pediatric cold drugs, involving 11 approvals There are 4 kinds of drugs for paediatric anorexia, involving 5 approvals Four other pediatric drugs are all exclusive There are 2 pediatric convulsive drugs, involving 33 approvals One pediatric supplement is the exclusive product One paediatric antidiarrheal, involving 2 approvals The proportion of oral liquid and granule is the largest Due to the low age of children, it is not suitable to take tablets, capsules and other large-scale drugs 29 pediatric Chinese patent medicines newly added in the new medical insurance catalogue account for the largest proportion of oral liquid 12 varieties are distributed in four treatment fields: pediatric cold medicine, pediatric convulsive medicine, pediatric anorexia medicine and pediatric cough and expectorant medicine Secondly, there are 11 kinds of granules, which are distributed in six therapeutic fields: pediatric supplementary nutrition, pediatric cold, pediatric convulsive drugs, other pediatric drugs, pediatric anorexia drugs and pediatric cough and expectorant drugs 69% of the 29 new products are exclusive varieties, and 20 of the 29 new pediatric Chinese patent medicines are exclusive varieties, accounting for nearly 69% Among them, Yaodu Pharmaceutical Group Co., Ltd has two exclusive varieties which have entered the new medical insurance catalogue Xiaoer Kechuanling mixture and Xiaoer Qingre Zhike mixture are used for children's cough and expectoration   In terms of listed companies, the exclusive products of Huashen group are Ergan qurening oral liquid, Kangyuan pharmaceutical jiuweixifeng granules, sunflower pharmaceutical xiaofeifeire Kechuan oral liquid, Meiluo pharmaceutical xiaofeireqing granules, Renhe pharmaceutical Huaji granules, Wuhan Jianmin Longmu Zhuanggu granules and Yabao pharmaceutical All kinds of children's Qingyan Jiere oral liquid have entered the new medical insurance catalogue In addition, among the new exclusive Chinese patent medicines for children, Xiaoer Shikou powder of Ulanhot ZhongMeng Pharmaceutical Co., Ltd deserves special attention The product belongs to Mongolian medicine, which is also a second-class Chinese medicine protection variety in China It is used for the treatment of light and medium-sized children with rotavirus enteritis Mongolian medicine differentiation is Bada ganxieyi The product is also the only paediatric drug among the 41 newly added ethnic medicines in the new medical insurance catalogue Top 10 products in key treatment areas have little change in medical insurance Cold, cough and anorexia are common diseases of children According to the data of minenet, in 2015, the market scale of paediatric antitussive and expectorant drugs and paediatric cold drugs exceeded 17 in China's urban public hospitals, county-level public hospitals, urban community centers and township health centers (hereinafter referred to as "China's public medical institutions") Billion yuan, pediatric anorexia drugs with nearly 930 million yuan ranked third The new varieties are mostly distributed in these three treatment areas, which shows that the policies are consistent with the market rules, and more close to the needs of patients From the current situation, the top ten products of the three pediatric key drug markets have little change in medical insurance, only Qingxuan Zhike granules have been adjusted from class B to class A, and Feire Kechuan oral liquid for children is a new product Qingxuan Zhike granule is the exclusive product of Suzhou Sinopharm group According to the data of minenet, the sales volume of the product in the pattern of Chinese patent medicine of public medical institutions in China has a rising trend in the past three years, with a growth rate of 177.68% in 2014 and 95.89% in 2015 This product has proved its value with its marketing achievements After it is adjusted to class a of medical insurance, it will further gain the opportunity to shine and heat in the whole country Xiaoer Feire Kechuan oral liquid is the exclusive variety of sunflower pharmaceutical industry, and also one of the more than 100 million varieties of the enterprise According to the 2016 performance express of sunflower pharmaceutical industry, the company's overall sales revenue increased steadily, with a year-on-year growth of 12.06% The two main products of the company, Xiaoer Feire Kechuan oral liquid and Hugan tablet, established a strong growth trend in 2016 by virtue of their efficacy and reputation, and drove the sales volume of varieties to increase rapidly With the medical insurance label, whether the children 's lung heat cough and asthma oral liquid can drive the company' s performance to rise again remains to be seen In addition, in other pediatric drug markets, the achievement of the exclusive product of Sichuan Kaijing pharmaceutical, xiaoerjinqiao granules, also deserves attention According to the data of mienei.com, xiaoerjinqiao granules has been ranked in the top three of the market in the past three years, and its sales in the pattern of Chinese patent medicine in public medical institutions in China in 2015 also exceeded 60 million yuan The new medical insurance catalog respects innovation and gives more choices From the new situation of Chinese patent medicines in pediatrics in the 2017 version of the drug catalog, it can be seen that exclusive varieties are still favored In recent years, the state has given a lot of support at the policy level Enterprises are more and more smooth on the road of innovation, and the value of both products and enterprises has been well reflected   Recently, Fujian Province published the sunshine purchase catalogue of joint price limit of drugs (the first batch), the maximum sales price limit of medical insurance and the payment settlement price of medical insurance According to the principle of setting the payment settlement price, the exclusive quality of Chinese patent medicine does not distinguish the drug property, and the payment settlement price is determined according to the maximum sales price limit of medical insurance * 0.8, which fully reflects the support of government policies for the Chinese patent medicine industry From the sales situation, these 20 new exclusive varieties are not all "sales king" It still needs to be verified by the market whether they can bring impact to top 10 products after being labeled with new medical insurance From the new quantity, it can also reveal a message that the government hopes to give doctors and patients more choice space, and such arrangement is more humanized.